Gasporox AB (publ) (GPX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gasporox AB (publ) (GPX) has a cash flow conversion efficiency ratio of 0.438x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr7.98 Million ≈ $858.78K USD) by net assets (Skr18.23 Million ≈ $1.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Gasporox AB (publ) market cap and net worth for the company's overall valuation and market capitalisation.
Gasporox AB (publ) - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Gasporox AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gasporox AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gasporox AB (publ) ranked by their cash flow conversion efficiency. Explore GPX cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enorama Pharma AB
ST:ERMA
|
0.330x |
|
Optima Prima Metal Sinergi
JK:OPMS
|
-0.014x |
|
Me Group International PLC
LSE:MEGP
|
0.180x |
|
Wide Open Agriculture Ltd
AU:WOA
|
-0.429x |
|
Activex Ltd
AU:AIV
|
-11.887x |
|
APOLLO GROUP-A
F:APO
|
0.090x |
|
Pentanet Ltd
AU:5GG
|
0.068x |
|
PEPTONIC MEDICAL
F:28L
|
-0.112x |
Annual Cash Flow Conversion Efficiency for Gasporox AB (publ) (2015–2025)
The table below shows the annual cash flow conversion efficiency of Gasporox AB (publ) from 2015 to 2025. View GPX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr19.86 Million ≈ $2.14 Million |
Skr-4.72 Million ≈ $-507.84K |
-0.238x | -245.54% |
| 2024-12-31 | Skr26.69 Million ≈ $2.87 Million |
Skr4.36 Million ≈ $468.88K |
0.163x | +13.28% |
| 2023-12-31 | Skr23.19 Million ≈ $2.50 Million |
Skr3.34 Million ≈ $359.65K |
0.144x | +395.93% |
| 2022-12-31 | Skr24.44 Million ≈ $2.63 Million |
Skr-1.19 Million ≈ $-128.06K |
-0.049x | +58.91% |
| 2021-12-31 | Skr28.63 Million ≈ $3.08 Million |
Skr-3.39 Million ≈ $-365.14K |
-0.119x | -529.01% |
| 2020-12-31 | Skr34.07 Million ≈ $3.67 Million |
Skr-642.00K ≈ $-69.09K |
-0.019x | +86.66% |
| 2019-12-31 | Skr32.97 Million ≈ $3.55 Million |
Skr-4.66 Million ≈ $-501.17K |
-0.141x | +36.89% |
| 2018-12-31 | Skr26.72 Million ≈ $2.88 Million |
Skr-5.98 Million ≈ $-643.65K |
-0.224x | -192.00% |
| 2017-12-31 | Skr14.38 Million ≈ $1.55 Million |
Skr-1.10 Million ≈ $-118.59K |
-0.077x | +70.55% |
| 2016-12-31 | Skr16.76 Million ≈ $1.80 Million |
Skr-4.36 Million ≈ $-469.53K |
-0.260x | +80.35% |
| 2015-12-31 | Skr4.33 Million ≈ $465.76K |
Skr-5.73 Million ≈ $-617.07K |
-1.325x | -- |
About Gasporox AB (publ)
Gasporox AB (publ) engages in the development and commercialization of tunable diode laser absorption spectroscopy technology in Sweden. The company offers instruments, such as GPX1500 vial, GPX1500 film pharma, and GPX1500 film food; linearch machines; VialArch, BottleArch, AutoMAP pharma and food, and CellSpect sensors; and GPX HMI software. It also provides laboratory services, including alpha… Read more